Stay updated on Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial
Sign up to get notified when there's something new on the Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial page.

Latest updates to the Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial page
- Check7 days agoChange DetectedA new history entry on 2026-05-04 adds updates to the Study Status and Contacts/Locations sections, linked to versions 436 (2026-05-01) and 435 (2026-04-30); the 2026-04-13 entry was deleted.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now shows the site software revision version as v3.5.3 instead of v3.5.2, indicating an update to the ClinicalTrials.gov interface/system rather than the underlying study record.SummaryDifference0.0%

- Check28 days agoChange DetectedOn 2026-04-13 a new page revision (v3.5.2) was added with a Study Status entry (ID 434). The older revision (v3.5.0) was removed.SummaryDifference0.1%

- Check35 days agoChange DetectedNew version entries dated 2026-04-04 to 2026-04-09 include Study Status updates in the record history.SummaryDifference0.2%

- Check42 days agoChange DetectedNew record versions 424–428 dated 2026-03-26 to 2026-04-02 have been added, including Study Status updates in the history.SummaryDifference0.2%

- Check50 days agoChange DetectedNew history entries were added for Study Status on 2026-03-25 and earlier dates (versions 422–418), updating the record's status timeline.SummaryDifference0.2%

Stay in the know with updates to Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparison of Pembrolizumab Timing in High-Risk Melanoma Clinical Trial page.